Alzheimer's Disease (AD)
Patient Condition
The patient developed memory loss in early 2023, which affected daily life. The patient was admitted to Peking Union Medical College Hospital, with an MMSE score of 22 points, cognitive assessment showed mild AD, cerebrospinal fluid examination supported the diagnosis of AD, and APOE ε4 heterozygous.
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| Comprehensive assessment of advanced AD | ||
| Gantenerumab subcutaneous injection + symptom management | ||
| Strengthen cognitive stimulation + caregivers support | ||
| Long-term maintenance and palliative care |
Treatment Outcome
| before | MMSE score is 22 points, memory is significantly reduced, affects daily life, and family members are worried |
|---|---|
| after | MMSE score of 27 points (improvement of 5 points), memory was significantly improved, daily life was completely self-reliant, and family satisfaction was high |
| highlight | Sino-US collaborative treatment, excellent early intervention results |